On Dec. 6, 2023, Anixa Biosciences announced updated positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial was conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense.

Patients who had been curatively treated for TNBC received three vaccinations given once every two weeks. IFNγ and IL-17, which are T cell immune response indicators (cellular immunity), and antibody production (B cell humoral immunity) were measured to evaluate the vaccination effect.

Data from the 16 patients treated to date showed that the majority of patients developed ELISpot (T-cell) responses that met the rigorous protocol-specified definition of an immune response, with a measurable but lesser magnitude of response noted in the remaining patients. Anixa and Cleveland Clinic plan to investigate additional intermediate dose levels and continue studying the vaccine’s safety and immunologic effects in two additional patient cohorts.